Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence,Nature Reviews Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Nat. Rev. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
Nature Reviews Gastroenterology & Hepatology ( IF 65.1 ) Pub Date : 2024-02-12 , DOI: 10.1038/s41575-024-00904-5
Jordan Hindson

A multicentre, randomized phase II trial in China assessed use of sintilimab, a PD1 inhibitor, as adjuvant therapy in patients with hepatocellular carcinoma (HCC) with microvascular invasion who had undergone curative resection. These patients are at high risk of recurrence. Patients (n = 198) were randomized to sintilimab (intravenous injections every 3 weeks for eight cycles) or active surveillance. The primary endpoint of recurrence-free survival (RFS) was met: median RFS was 27.7 and 15.5 months (P = 0.002) in the sintilimab group and control group, respectively, after a median follow-up period of 23.3 months. Of patients receiving sintilimab, 12.4% had grade 3 or 4 treatment-related adverse events.

更新日期：2024-02-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>